Led · Seed · Jul 2024

Plurio is a San Francisco–based MarTech startup developing an AI-driven "autonomous agent" that automates and optimizes marketers’ digital ad campaigns across a variety of channels. The platform is designed to handle campaign setup, budget allocation, and performance optimization without continuous human oversight. By leveraging machine-learning algorithms, Plurio aims to improve return on ad spend and reduce the manual workload for marketing teams. The company, led by CEO Seva Ustinov, recently rebranded from Elly Analytics as it sharpens its focus on full-funnel campaign automation. Fresh capital will be directed toward expanding product development and scaling operations. No specific user, revenue, or other operating metrics were disclosed in the funding announcement.

Participated · Equity · Jul 2020

Cardiva Medical is a privately held medical device company focused on transforming vascular closure with its VASCADE and VASCADE MVP systems. VASCADE has been PMA-approved by the FDA since 2013 and demonstrated a statistically significant reduction in access-site complications in the randomized RESPECT trial. VASCADE MVP is the only marketed vessel closure technology designed specifically for electrophysiology procedures and received PMA approval in late 2018 after the AMBULATE trial. The company announced a $45 million equity financing to support continued commercial expansion of these systems and to fund other clinical and operational initiatives. Cardiva targets the more than 5.5 million catheter-based coronary, peripheral, and electrophysiology procedures in the U.S. that require access-site closure each year. The company is headquartered in Santa Clara, California, and has received industry recognition including the Shingo Bronze Medallion. Cardiva Medical is a privately held medical device company headquartered in Santa Clara, California, focused on developing and commercializing vascular closure technologies. Its flagship product, the FDA‑approved and CE‑marked VASCADE Vascular Closure System, is commercially available in the United States and demonstrated a statistically significant reduction in access site complications in the randomized RESPECT study. The company is advancing an investigational mid‑bore vein closure system through the IDE AMBULATE trial, which targets 6–12 French access sheaths used in cardiac ablation and other procedures. AMBULATE is a prospective, multi‑center, randomized, controlled study enrolling 204 patients across U.S. sites to compare Cardiva's system to standard manual compression and to shorten time to ambulation. Cardiva reported a high rate of VASCADE sales growth and recently closed on an additional $11 million, bringing total equity and debt financing in the current round to $41 million. Proceeds will fund U.S. commercial expansion of VASCADE and support the AMBULATE trial. Cardiva Medical develops and commercializes the VASCADE Vascular Closure System. The company plans to use new funding to continue commercial expansion of VASCADE and to develop proprietary closure technologies. Cardiva reported a $30m equity financing led by affiliates of Luther King Capital Management, PTV Healthcare Capital and the Canepa Advanced Healthcare Fund. The company is led by President and CEO John Russell. VASCADE demonstrated a statistically significant reduction in access site complications in the prospective, randomized RESPECT clinical trial. The RESPECT study included 420 patients at 20 U.S. centers comparing VASCADE to manual compression for femoral arterial closure. Cardiva Medical develops and commercializes vascular closure technology designed to help the body heal itself following catheterization procedures. Its product line includes VASCADE, a vascular closure system, and the Catalyst II and Catalyst III devices for aiding manual compression. VASCADE received FDA approval in 2013 and CE marking in 2012; Catalyst II and III were cleared by the FDA in 2007 and 2009, respectively. The company says it is ramping up commercialization of its vascular closure products. To support that commercialization, Cardiva has taken on a senior secured credit facility to provide working capital. Cardiva is privately held, was founded in 2002, and is based in Sunnyvale, California. Cardiva Medical develops a vascular closure system and is based in Sunnyvale, California. Its vascular closure system received FDA approval in February. According to an SEC filing dated July 29, the company has raised nearly all of the $3.5 million it was seeking, with only $2,367 remaining to close the deal. About this time last year the company completed the third tranche of a Series 2 financing. The filing lists officers and directors including President and CEO Charles Maroney, founder and former CEO Augustine Lien, and Co‑Founder and VP of R&D Zia Yassinzadeh, among others. The company could not be reached for comment and the article does not disclose revenue, users, or investor details.

Participated · Equity · Jan 2018

Intuity Medical is a Sunnyvale, California-based medical device company focused on simplifying diabetes care through its flagship POGO Automatic Blood Glucose Monitoring System. POGO integrates lancing, blood collection, and glucose analysis into a single step using a self-contained 10-test cartridge, removing the need for separate strips and lancets. The device delivers a result after a four-second countdown from a 0.25-microliter blood sample and received FDA clearance in April 2016. Intuity pairs POGO with its proprietary cloud platform, Patterns Diabetes Management System, to help patients and healthcare professionals identify glucose trends. The company is currently advancing commercialization of POGO while enhancing its digital management capabilities. Financially, Intuity has attracted significant venture backing, most recently expanding its Series 3 equity financing to $55 million.

Participated · Series D · Feb 2013

Intersect ENT develops and commercializes absorbable, steroid-releasing sinus stents, led by its flagship product Propel and a smaller Propel Mini. Propel received FDA approval in August 2011, and Propel Mini won approval the following fall. The stents are implanted after sinus surgery to keep passages open and slowly release steroid locally, reducing the need for follow-up operations. To date more than 6,000 patients have been treated with Propel. The company moved into a new 32,000-square-foot Menlo Park facility to house business and manufacturing as it scales production. It is pursuing U.S. commercial expansion and planning clinical studies for an office-based treatment for chronic sinusitis. Intersect ENT develops a bioabsorbable drug-eluting stent to treat patients with chronic sinusitis. The device is intended for use by Ear, Nose, and Throat (ENT) surgeons. The company recently closed a $30M round of financing and plans to use the funds to commercialize its initial product. It also intends to build a broader portfolio of products addressing conditions treated by ENT surgeons. Intersect ENT is based in Palo Alto, California.

Led · Equity · Jan 2013

Tryton Medical is the leading developer of stents designed to treat coronary bifurcation lesions. Its core product, the Tryton Side Branch Stent System, uses proprietary Tri‑ZONE® technology and a cobalt‑chromium design deployed in the side branch via a standard single‑wire balloon‑expandable delivery system while a conventional drug‑eluting stent is placed in the main vessel. The Tryton Side Branch Stent has been used to treat more than 10,000 patients worldwide, is commercially available in multiple countries across Europe, the Middle East & Africa, is investigational in the U.S., and is not available in Japan. Tryton is pursuing U.S. market clearance through the Pivotal IDE Trial and the Tryton IDE Extended Access Registry, with results from both intended for submission to the FDA. The company plans to develop the left main market opportunity based on a CE approved left main stent indication for its Tryton Side Branch Stent. Tryton completed an initial closing of a $20 million private equity financing to support registry enrollment, the FDA submission, and left main market development. Tryton Medical develops stent systems to treat coronary bifurcation lesions using its proprietary Tri-zone technology. Its cobalt chromium stent is deployed in the side branch with a standard single-wire balloon-expandable delivery system, after which a conventional drug-eluting stent is placed in the main vessel. The stent system has received CE Mark and is commercially available across Europe, Russia and the Middle East, while in the United States it is approved for investigational use only. The company, founded in 2003 and led by president and CEO Shawn P. McCarthy, intends to support a U.S. FDA submission this year and to expand its platform with a new stent system targeting left main disease. Tryton also plans to accelerate access into critical global markets, specifically in Asia. It recently held an initial closing of an aggregate $24M financing to support those plans. Tryton Medical, located in Durham, NC, develops novel stent systems for the treatment of coronary bifurcation lesions. Its Tryton Side Branch Stent System has CE Mark approval in Europe and has been implanted in more than 2,500 patients. The company was founded in 2003 by Aaron V. Kaplan, M.D., and Dan Cole. Tryton is privately held and venture-backed by Arnerich Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest Ventures. Square 1 Bank has extended a $5 million term loan credit facility to the company. With the new facility, Tryton is enrolling in a pivotal U.S. clinical trial to advance its device toward broader market access. Tryton Medical develops the Tryton Side Branch Stent System, a dedicated strategy for treating atherosclerotic lesions in the side branch at coronary bifurcations. The system has shown excellent six-month clinical and angiographic results in a first-in-man study and similarly strong six-month clinical outcomes from nearly 200 patients across four registries, with a target lesion revascularization rate under 4%. The device has received CE Mark approval and is commercially available in 21 countries across Europe and the Middle East. It is not approved for use in the United States. The company plans to use new financing to conduct a U.S. pivotal trial and to drive broader international product adoption. Tryton is based in Durham, North Carolina.